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The emergence of Escherichia coli that produce extended spectrum β-lactamases (ESBLs) and are multidrug resistant (MDR)
poses antibiotic management problems. Forty-seven E. coli isolates from various public hospitals in Malaysia were studied. All
isolates were sensitive to imipenem whereas 36 were MDR (resistant to 2 or more classes of antibiotics). PCR detection using
gene-specific primers showed that 87.5% of the ESBL-producing E. coli harbored the blaTEM gene. Other ESBL-encoding genes
detected were blaOXA, blaSHV, and blaCTX-M. Integron-encoded integrases were detected in 55.3% of isolates, with class 1 integron-
encoded intI1 integrase being the majority. Amplification and sequence analysis of the 5′CS region of the integrons showed known
antibiotic resistance-encoding gene cassettes of various sizes that were inserted within the respective integrons. Conjugation and
transformation experiments indicated that some of the antibiotic resistance genes were likely plasmid-encoded and transmissible.
All 47 isolates were subtyped by PFGE and PCR-based fingerprinting using random amplified polymorphic DNA (RAPD),
repetitive extragenic palindromes (REPs), and enterobacterial repetitive intergenic consensus (ERIC). These isolates were very
diverse and heterogeneous. PFGE, ERIC, and REP-PCR methods were more discriminative than RAPD in subtyping the E. coli
isolates.
Copyright © 2009 King-Ting Lim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Escherichia coli are one of the main bacterial pathogens
responsible for nosocomial infections especially in immuno-
compromised patients [1]. Extended-spectrum β-lactamases
(ESBLs) are enzymes produced by Gram-negative bacilli
that mediate resistance to penicillin, cephalosporins, and
monobactams and are commonly recognized in Enterobac-
teriaceae and Pseudomonas aeruginosa [2]. Although most
ESBLs are mutants of TEM and SHV enzymes, the CTX-M
type β-lactamases which have become important, originated
from β-lactamases found in environmental species of the
genus Kluyvera, and this enzyme hydrolyzes cefotaxime and
cefriaxone but is weakly active against ceftazidime [3, 4].
These enzymes are present worldwide with more than 50
variants [4]. The emergence of ESBL-producers along with
multiple resistant isolates poses a serious problem in the
hospital setting. The widespread uses of antibiotics coupled
with the transmissibility of resistance determinants mediated
by plasmids, transposons, and gene cassettes in integrons are
factors that contribute to the increase in antibiotic resistance
in bacterial pathogens [1].
Rapid and discriminative subtyping methods are essen-
tial for determining the epidemiology of isolates in order
to design rational control methods. Available subtyping
methods for E. coli include PFGE, plasmid profiling, ribo-
typing and PCR-based typing methods such as arbitrary-
primed PCR, repetitive extragenic palindromes (REPs), and
enterobacterial repetitive intergenic consensus (ERIC) [5].
A study fromMalaysia reported the presence of the ampC
gene and SHV-5 ESBL in clinical isolates of E. coli [6].
2 Journal of Biomedicine and Biotechnology
However, the genotypic characterization of other resistant
isolates has not been reported so far. The objectives of this
study were to determine the antimicrobial resistance and
ESBL profiles of E. coli isolated from 5 public Malaysian
hospitals and to determine their genetic diversity using PCR-
based fingerprinting techniques and PFGE. The presence of
resistance genes and integrons was also determined via PCR,
and their transferability was determined by conjugation and
transformation.
2. Materials and Methods
2.1. Bacterial Strains. In this retrospective study, 47 nonre-
peat E. coli isolates were collected in 2004 from 47 diﬀerent
patients selected randomly from intensive care units of 5
public hospitals located in diﬀerent parts of Malaysia. The
participating hospitals were Kota Bharu Hospital (n = 10),
Sultanah Aminah Hospital (n = 23), Kuala Lumpur Hospital
(n = 10), Ipoh Hospital (n = 2), and Queen Elizabeth
Hospital (n = 2). The isolates were from tracheal aspirates
(n = 18), urine (n = 6), body fluids (n = 1), blood
(n = 7), pus (n = 6), bile (n = 1), catheter tips (n = 6),
and unknown (n = 2). They were identified by standard
laboratory methods in the respective hospitals. They were
stored in cryovials containing Luria-Bertani broth with 50%
glycerol (Invitrogen, USA) at −20◦C and −85◦C.
2.2. Genotyping by RAPD, REP, and ERIC. Crude DNA from
the E. coli obtained by direct cell lysate was used for random
amplified polymorphic DNA (RAPD) analysis using primers
OPAB04 [7] and OPB17 [8] with cycling conditions as
previously described (Table 1).
Enterobacterial repetitive intergenic consensus (ERIC)
analysis was performed using primer ERIC-1R (Operon
Biotechnologies GmBH, Germany) while repetitive extra-
genic palindrome (REP) analysis was carried out using
REP oligonucleotides (Operon Biotechnologies GmBH, Ger-
many) as primers previously reported [9] (Table 1).
Each PCR reaction was carried out in a 25 μL volume
using 1.5U of Taq DNA polymerase (Promega, Madi-
son, Wis, USA) in the reaction buﬀer provided by the
manufacturer containing 2.5mM MgCl2, 50 μM of each
deoxynucleoside triphosphate, 0.3 μM of the selected primer
and 5 μL of DNA template. Aliquots (10 μL) of each PCR
product were subjected to electrophoresis on 1.5% agarose
gel.
2.3. Genotyping by PFGE. PFGE was performed according to
previously described protocols [20] withminor variations.
Equal volumes of 1% Seakem Gold agarose (Cambrex Bio
Science, Rockland, USA) and standardized cell suspension
(OD610 = 1.4; approximately 1 × 108 cfu/mL) were mixed to
form agarose plugs, and the bacteria lysed within the plugs
with cell lysis buﬀer (50mM Tris; 50mM EDTA (pH 8.0),
1% Sacrosine, 1mg/mL proteinase K) and incubated at 54◦C
for 3 hours. Plugs were then washed with sterile deionised
water (twice) and TE buﬀer (4 times), then digested with 12
U of XbaI (Promega, Madison, Wis, USA), and incubated
overnight at 37◦C. The XbaI-digested DNA was separated
on a CHEF-DRIII (BioRad, Hercules, CA, USA) with pulse
times of 2.2–54.2 seconds at 200V for 24 hours, and gels were
photographed under UV light after staining with 0.5 μg/mL
ethidium bromide.
2.4. Fingerprint Pattern Analysis. The banding patterns gen-
erated by RAPD, ERIC-PCR, REP-PCR, and PFGE were
analyzed using GelCompar II, version 2.5 (Applied Maths,
Kortrijk, Belgium). PCR fingerprints and PFGE profiles were
assigned arbitrary designation and analyzed by defining a
similarity (Dice) coeﬃcient F [21]. Cluster analysis based on
the unweighted pair group method with arithmetic averages
(UPGMA) with a position tolerance of 0.15 was done using
the GelCompar II software.
2.5. Antimicrobial Susceptibility Testing and Screening for
ESBL. Eighteen antimicrobial agents were tested by the
disk diﬀusion method in accordance with CLSI guide-
lines [22]: ampicillin 10 μg, piperacillin 100 μg, amoxicillin-
clavulanic acid 20 μg/10 μg, cefriaxone 30 μg, ceftazidime
30 μg, cefepime 30 μg, cefoperazone 75 μg, aztreonam
30 μg, imipenem 10 μg, amikacin 30 μg, streptomycin 10 μg,
gentamicin 30 μg, kanamycin 30 μg, tetracycline 30 μg,
chloramphenicol 30 μg, ciprofloxacin 5 μg, trimethoprim-
sulfamethoxazole 75 μg, and nalidixic acid 30 μg (Oxoid Ltd.,
Basingtoke, Hampshire, England). Isolates were screened for
ESBL production by the CLSI disk diﬀusion method using
cefriaxone 30 μg, ceftazidime 30 μg, and aztreonam 30 μg
[22]. The double-disk synergy test was performed according
to established protocols and results interpreted as described
previously [23].
Phenotypic confirmatory test was performed with 30 μg
ceftazidime, 30/10 μg ceftazidime-clavulanic acid (Becton,
Diskson & Company, Maryland, USA), 30 μg cefotaxime
and 30/10 μg cefotaxime-clavulanic acid (Becton, Diskson &
Company, Maryland, USA) disks on Mueller-Hinton agar.
The results were interpreted as described [22]. E. coli isolates
ATCC 25922 and ATCC 35218, Klebsiella pneumoniae ATCC
700603, and P. aeruginosa ATCC 27853 were used as controls.
2.6. Detection of ESBL Genes. β-lactamase genes (blaTEM,
blaSHV, blaCTX-M, blaOXA, blaVEB, blaDHA) were detected by
PCR using reverse and forward primer pairs listed in Table 1.
Boiled suspension of bacterial cells was used as DNA tem-
plate, and cycling parameters were as previously described
[10–13] withminor modifications (Table 1). Primers 1R,
1, 8F, 8R, 2F, 2R, 9F, and 9R [15] were used for further
subgrouping of the blaCTX-M gene into CTX-M groups 1, 2,
8/25, and 9. All amplified products obtained were sequenced
to validate their identities.
Two ESBL-producing isolates (EC19 and EC31) were
further tested by using primers specific for blaACT, blaGES,
blaVIM, blaPER, and blaFOX genes using conditions as listed in
Table 1.
Clinical isolates of E. coli were used as the positive
controls for blaTEM, blaSHV, blaCTX-M, and blaOXA genes.
No positive controls were available for detection of blaVEB,
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Table 1: Primer sequences and PCR conditions.
Primers Oligonucleotide sequence (5′ to 3′) PCR conditions Reference
Expected
size (bp)
TEM-F
TEM-R
ATGAGTATTCAACATTTCCG
CTGACAGTTACCAATGCTTA
1 cycle of 5 min at 96
o
C; 35 cycles of
1min at 96
o
C, 1min at 58
o
C, 1min at
72
o
C; 1 cycle of 10min at 72
o
C
[10] 867
SHV-F
SHV-R
GGTTATGCGTTATATTCGCC
TTAGCGTTGCCAGTGCTC
1 cycle of 5min at 96
o
C; 35 cycles of
1min at 96
o
C, 1min at 60
o
C, 1min at
72
o
C; 1 cycle of 10min at 72
o
C
[10] 867
OXA-F
OXA-R
ACACAATACATATCAACTTCGC
AGTGTGTTTAGAATGGTGATC
1 cycle of 5min at 96
o
C; 35 cycles of
1min at 96
o
C, 1min at 60
o
C, 2min at
72
o
C; 1 cycle of 10min at 72
o
C
[10] 885
CTX-MU1
CTX-MU2
ATGTGCAGYACCAGTAARGT
TGGGTRAARTARGTSACCAGA
1 cycle of 7min at 94
o
C; 35 cycles of
50 sec at 94
o
C, 40 sec at 50
o
C, 1min at
72
o
C; 1 cycle of 5min at 72
o
C
[11] 593
DHA-1U
DHA-1L
CACACGGAAGGTTAATTCTGA
CGGTTATACGGCTGAACCTG
1 cycle of 5min at 94
o
C; 35 cycles of
30 sec at 94
o
C, 45 sec at 50
o
C, 1min at
72
o
C; 1 cycle of 8min at 72
o
C
[12] 970
VEB-1A
VEB-1B
CGACTTCCATTTCCCGATGC
GGACTCTGCAACAAATACGC
1 cycle of 5min at 96
o
C; 30 cycles of
1min at 96
o
C, 1min at 55
o
C, 2min at
72
o
C; 1 cycle of 10min at 72
o
C
[13] 1014
IntI1-F
IntI1-R
GGTCAAGGATCTGGATTTGG
ACATGCGTGTAAATCATCGTC
1 cycle of 12min at 94
o
C; 35 cycles of
1min at 94
o
C, 1min at 57
o
C, 2min at
72
o
C; 1 cycle of 10min at 72
o
C
[14] 500
5′CS
3′CS
GGCATCCAAGCAGCAAG
AAGCAGACTTGACCTGA
1 cycle of 10min at 94
o
C; 35 cycles of
1min at 94
o
C, 1min at 54
o
C, 2min at
72
o
C; 1 cycle of 8min at 72
o
C
[14] —
IntI2-F
IntI2-R
CACGGATATGCGACAAAAAGGT
GTAGCAAACGAGTGACGAAATG
Same as for int1 [14] 740
attI2-F
orfX-R
GACGGCATGCACGATTTGTA
GATGCCATCGCAAGTACGAG
1 cycle of 12min at 94
o
C; 35 cycles of
1min at 94
o
C, 1min at 59.5
o
C, 3.5min
at 72
o
C; 1 cycle of 10min at 72
o
C
[14] 2000
IntI3-F
IntI3-R
AGTGGGTGGCGAATGAGTG
TGT TCT TGT ATC GGC AGG TG
1 cycle of 12min at 94
o
C; 30 cycles of
30 sec at 94
o
C, 30 sec at 60
o
C, 1min at
72
o
C; 1 cycle of 8min at 72
o
C
[14] 600
1, 8F
1R
2F
2R
8R
1,8F
9F
9R
GCSATGTGCAGCACCAGTAA
ACAAACCGTYGGTGACGATT
CTCAATASCGCCATTCCAGG
CCGTGGGTTACGATTTTCGC
GTCGTACCATAAYCRCCGCT
GCSATGTGCAGCACCAGTAA
ARTGCAACGGATGATGTYCG
GAT GAT TCT CGC CGC TGA AG
1 cycle of 5min at 95
o
C; 30 cycles of
30 sec at 95
o
C, 30 sec at 63
o
C, and 1min
at 72
o
C; 10min at 72
o
C.
[15]
666
355
529
846
GES-A
GES-B
CTTCATTCACGCACTATTAC
TAACTTGACCGACAGAGG
1 cycle of 5min at 95
o
C; 30 cycles of
1min at 95
o
C, 45 sec at 55
o
C, 1min 30
sec at 72
o
C; 1 cycle of 8min at 72
o
C
[16] 827
VIM-F
VIM-R
AGTGGTGAGTATCCGACAG
ATGAAAGTGCGTGGAGAC
Same as GES-A [17] 225
FOXUP1F
FOXUP1R
CACCACGAGAATAACC
GCCTTGAACTCGACCG
Same as GES-A [18] 1184
NHAmpCF
NHAmpR
ATTCGTATGCTGGATCTCGCCACC
CATGACCCAGTTCGCCATATCCTG
Same as GES-A [18] 396
PER-A
PER-B
GGGACARTCSKATGAATGTCA
GGGYSGCTTAGATAGTGCTGAT
Same as GES-A —
OPAB04 GCACG CGTT
1 cycle of 2min 30 sec at 94
o
C; 35 cycles
of 30 sec at 94
o
C, 1min at 47
o
C, and
1min at 72
o
C; 4min at 72
o
C.
[7] —
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Table 1: Continued.
Primers Oligonucleotide sequence (5′ to 3′) PCR conditions Reference
Expected
size (bp)
OPB17 AGGGAACGAG Same as OPAB04 [8] —
REP GCGCCG ICATGCGGCATT
1 cycle of 7min at 94
o
C; 30 cycles of
30 sec at 94
o
C, 1min at 44
o
C, 8min at
72
o
C for 30 cycles; 16min at 65
o
C.
[9] —
ERIC-1R ATGTAACGTCCTGGGGATTCAC
1 cycle of 2min and 30 sec at 94
o
C; 35
cycles of 30 sec at 94
o
C, 1min at 47
o
C,
1min at 72
o
C; 1 cycle of 4min at 72
o
C
[19] —
blaACT, blaGES, blaVIM, blaPER, blaFOX, and blaDHA genes and
subgrouping of CTX-M group amplified 2, 8/25, and 9.
2.7. Detection of Class 1, 2, and 3 Integrons. Class 1, 2, and
3 integrons were detected by PCR using established primers
and conditions as listed in Table 1. Selected amplified
products were sequenced to corroborate their identities.
2.8. Transfer of Antibiotic Resistance Determinants. Transfer
of resistance genes was attempted in broth using nalidixic
resistant recipient E. coli JM109 (endA1, recA1, gyrA96,
thi, hsdR17 (rk−, mk+), relA1, supE44, λ-, Δ (lac-proAB),
(F′, traD36, proAB, lacIqZΔZM15). Transconjugants were
selected on Luria-Bertani agar supplemented with ampicillin
(100 μg/mL) plus nalidixic acid (100 μg/mL) (Sigma Aldrich,
USA).
Transformation experiments were carried out for isolates
in which conjugation failed to produce positive results.
Plasmid DNA was extracted from ESBL-producing E. coli
using the QIAprep Spin Miniprep Kit (QIAGEN, Hilden,
Germany) and was transformed by electroporation into
electrocompetent E. coli DH10B (F−mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZ ΔlacX74 recA1 endA1 araD139 Δ (ara,
leu)7697 galU galK λ−rpsL nupG tonA). Transformants were
selected on Luria-Bertani agar plates containing 100 μg/mL
ampicillin (Sigma Aldrich, USA).
Size determination of the plasmids from transconjugants
and transformants was carried out by digestion with EcoRI
or SphI (Promega, Madison, Wis, USA), and the products
separated in 0.8% agarose gels at 70V for 4 hours.
3. Results
3.1. PCR-Based Fingerprinting. Three PCR-based DNA fin-
gerprinting methods were used to subtype the 47 E. coli
isolates. ERIC-PCR analysis diﬀerentiated the 47 isolates
into 45 unique profiles (F = 0.54–1.0) whereas RAPD
using the OPAB04 and OPB17 primers generated 44 and 43
profiles, respectively, (F = 0.41–1.0 for the OPAB04 primer
and F = 0.36–1.0 for the OPB17 primer, see Figures 1(a)
and 1(b)). REP-PCR diﬀerentiated the 47 isolates into 45
distinct profiles (F = 0.53–1.0, see Figure 1(c)). All three
PCR-based methods were reproducible as identical profiles
were obtained in separate experiments using the same set of
isolates.
Two isolates, EC14 and EC34, from the same hospital
but from diﬀerent wards, yielded identical profiles by all
the 3 methods. Two other blood isolates, EC12 and EC24,
from 2 diﬀerent patients in the same ward, were also
indistinguishable by their ERIC, REP, and RAPD profiles.
ESBL-producing isolates EC4, EC9, and EC20 were clonally
related by both RAPD and REP-PCR. Isolates EC4 and EC9
were indistinguishable by RAPD using the OPAB04 primer
whereas isolates EC4 and EC20 were indistinguishable by
RAPD using the OPB17 primer. However, isolates EC4 and
EC9 were in the same cluster (92% similarity) based on their
ERIC-PCR profiles.
3.2. PFGE with XbaI-Digested Genomic DNA. XbaI-digested
genomic DNA of the 47 E. coli isolates resulted in 44 distinct
pulsed-field profiles (PFPs) comprising 12–26 restriction
fragments. The 2 E. coli strains that had identical ERIC-PCR,
REP-PCR and RAPD profiles (i.e., EC12 and EC24) were
similarly indistinguishable by their PFPs with both sharing
all 14 restriction fragments.
Two other isolates, EC1 and EC4 which were indistin-
guishable by PFGE but were distinguishable in their ERIC,
RAPD and REP-PCR profiles, had 39%–68% similarities.
Similarly, ERIC, RAPD, and REP-PCR diﬀerentiated isolates
EC37 and EC39 that displayed identical PFPs. Both EC37
and EC39 were isolated from the same hospital. On the
other hand, isolates EC14 and EC34 that displayed identical
ERIC, RAPD, and REP-PCR profiles could be diﬀerentiated
by PFGE (F = 0.81).
3.3. Combined Analysis. A dendrogram based on the com-
bined fingerprints generated by ERIC-PCR, RAPD, REP-
PCR, and PFGE was constructed (Figure 2). All the 47
isolates were diﬀerentiated into 46 combined subtypes
(Table 2). Two isolates, EC12 and EC24, with the combined
profile E12R12A11B12X11 were identical in their ERIC,
RAPD, REP, and PFGE profiles. Three other isolates (EC4,
EC9, and EC20) were grouped within the same cluster and
were clonally related (more than 85% similarity). Isolates
EC14 and EC34 were also grouped together within the same
cluster and were clonally related (more than 94% similarity).
3.4. Antimicrobial Susceptibility. The antibiotic resistant
rates for the E. coli isolates were as follows: ampicillin
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Figure 1: (a) Representative ERIC-PCR profiles for E. coli isolates. Lanes 1, 10, 20: 100 bp DNA ladder, lanes 2–4: EC1-EC3; lanes 5–9: EC17,
EC19, EC18, EC30, EC34, lanes 11–18: EC32, EC14, EC41, EC39, EC42, EC22, EC45, EC46; lane 19: negative control. (b) Representative
RAPD profiles for E. coli isolates. Lanes 1, 21: 1 kb DNA ladder; lane 2, 20: 100 bp DNA ladder; lanes 3–18: EC5, EC8, EC13, EC15, EC7,
EC44, EC12, EC24, EC25, EC29, EC35, EC40, EC26, EC43, EC46, EC47; lane 19: negative control. (c) Representative REP-PCR profiles for
E. coli isolates. Lane 1, 21: 1 kb DNA ladder; lane 2, 20: 100 bp DNA ladder; lanes 3–18: EC5, EC8, EC13, EC15, EC7, EC44, EC12, EC24,
EC25, EC29, EC35, EC26, EC40, EC43, EC46, EC47; lane 19: negative control. (d) Representative PFGE profiles for E. coli isolates. Lanes 1,
7, 14: Salmonella Braenderup H9812 Standard DNA marker; lanes 2–6: EC4, EC9, EC38, EC36, EC18; lanes 8–13: EC28, EC31, EC40, EC22,
EC45, EC46.
77%, piperacillin 64%, tetracycline 53%, trimethoprim-
sulfamethoxazole 43%, cefoperazone and kanamycin
30% each, nalidixic acid 28%, chloramphenicol 26%,
ciprofloxacin 23%, gentamicin 21%, amoxicillin-clavulanic
acid 17%, cefriaxone ceftazidime and aztreonam 11%
each, and amikacin 2%. All 47 isolates were sensitive to
imipenem. Majority of the isolates were sensitive to cefepime
except EC28, EC34, and EC37 that showed intermediate
susceptibility. Among them, 36 isolates (76.5%) were
multidrug-resistant. The cephalosporin resistant isolates
were also resistant to ampicillin and 71% of them resistant
to tetracycline. A large number of isolates that were
resistant to aminoglycosides (72%) were also resistant to
tetracycline.
Thirty-six (76.5%) isolates were presumptive ESBL
producers based on initial screening. Using the double-
disk synergy test, only 3 ESBL producing isolates were
detected. However, based on the phenotypic confirmatory
test, 10 isolates were found to be ESBL producers. All
isolates that tested positive for ESBL were also multidrug-
resistant.
3.5. Detection of Genes Encoding ESBLs. Established primers
were used on the genomic and plasmid DNA of the 47 E.
coli isolates for the following ESBL-encoding genes: blaTEM,
blaSHV, blaOXA, blaCTX-M, blaDHA, and blaVEB. The blaTEM-1
gene was detected in 35 (74.5%) whereas blaSHV-, blaCTX-M-,
and blaOXA-specific amplicons were detected in only 3, 8,
and 2 isolates, respectively. Of the 35 blaTEM isolates, 7 also
harbored blaCTX-M and 1 had blaSHV. Three ESBL genes were
detected in E. coli isolate EC7: blaSHV, blaOXA, and blaCTX-M.
blaDHA, and blaVEB were not detected in any of the isolates. All
blaTEM, blaSHV, and blaOXA genes were carried on plasmids
whereas 6 of the 8 blaCTX-M genes were plasmid-borne. No
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E34R34A33B33X34
E21R21A20B20X20
E43R43A42B41X42
E05R05A05B05X04
E42R42A41B40X41
E38R38A37B37X37
E28R28A27B27X27
E12R12A11B12X11
E12R12A11B12X11
E27R27A26B26X26
E08R08A08B08X07
E41R41A40B08X40
E25R25A24B24X24
E07R07A07B07X06
E13R13A12B13X12
E01R02A02B02X02
E31R31A30B30X30
E40R40A39B39X39
E15R15A14B15X14
E33R33A32B32X33
E04R04A04B04X01
E20R20A19B04X19
E09R09A04B09X08
E01R01A01B01X01
E16R16A15B16X15
E11R11A10B11X10
E32R32A31B31X31
E45R45A44B43X44
E17R17A16B17X16
E06R06A06B06X05
E35R35A34B34X35
E30R30A29B29X29
E37R37A36B36X35
E10R10A09B10X09
E36R36A35B35X36
E23R24A23B23X23
E19R19A18B19X18
E03R03A03B03X03
Combined profiles 55 60 65 70 75 80 85 90 95
Figure 2: Dendrogram generated using UPGMA based on Dice coeﬃcients of similarity for the clustering of the E. coli combined profile.
The dotted blue vertical line indicates 80% similarity level.
ESBL-encoding gene was detected in 2 presumptive ESBL-
producers, EC19 and EC31. Sequencing of the amplified
products indicated complete identity with the respective gene
sequences (i.e., blaTEM, blaSHV, blaOXA, and blaCTX-M) in the
NCBI database. Further analysis of the blaTEM sequences
indicated that the E. coli isolates harbored the TEM-1
subgroup whereas for blaOXA, the subgroup found in the
isolates was OXA-1. In the case of the blaCTX-M gene, DNA
sequences analysis indicated that 3 of the 8 isolates detected
belonged either to subgroup CTX-M-15 or to subgroup
CTX-M-28. However, it was not possible to further subgroup
the remaining 5 blaCTX-M genes, as the primers used did not
amplify the entire blaCTX-M reading frame. The subsequent
use of primers 1R, 1, 8F, 2F, 2R, 8R, 9F, and 9R [15] to further
subgroup the 5 blaCTX-M genes could only indicate that they
did not belong to subgroups 1, 2, 8/25, and 9. Similarly, we
were unable to subgroup the blaSHV genes as the primers
used only amplified a portion of the gene and not the entire
reading frame.
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Table 2: Antimicrobial resistance, size of plasmids and ESBL genes detected in the selected donor E. coli isolates, and their respective
transconjugants and transformants.
No. Resistance
profile
ESBL-
encoding
gene
detected by
PCR
Plasmid
donor
(kb)
Plasmid transfor-
mant/transconjugant
(kb)
Resistance profile of
transformant/
transconjugant
ESBL-
encoding gene
transferred
Mode of transfer
EC7
AMP, PIP,
TET, CRO,
FEP, NAL,
SXT, CHL,
CFP, CAZ,
KAN,
ATM
blaOXA,
blaSHV,
blaCTX-M
135 55
AMP, PIP, TET, CRO,
FEP, NAL, SXT, CFP,
KAN, ATM
blaOXA, blaSHV, Transformation
EC10
AMP, PIP,
TET, NAL,
SXT, CHL,
CAZ,
KAN, CIP,
STR, GEN
blaTEM 310 310
AMP, PIP, TET, NAL,
SXT, CHL, CIP, STR,
GEN
blaTEM Transformation
EC12
AMP, PIP,
TET, NAL,
SXT, CHL,
KAN, STR
blaTEM 50 50
AMP, PIP, TET, SXT,
KAN, STR
blaTEM Transformation
EC18
AMP, PIP,
TET, SXT,
STR, CRO
blaTEM 190 190 AMP blaTEM Conjugation
EC24
AMP, PIP,
TET, NAL,
SXT, CHL,
KAN, CIP,
GEN
blaTEM,
blaCTX-M
60 60
AMP, PIP, TET, NAL,
SXT, CHL, CIP, GEN
blaTEM,
blaCTX-M
Transformation
EC31
AMP, PIP,
TET, SXT,
CHL, CFP,
KAN,
CRO, STR
ND 90 40 AMP, PIP, SXT, CFP ND Conjugation
EC36
AMP, PIP,
TET, SXT,
CFP, CIP,
STR, KAN,
GEN,
NAL,
CHL, SXT
blaTEM 300 300
AMP, PIP, TET, SXT,
CIP, STR, GEN, CHL,
NAL
blaTEM Transformation
EC46 AMP, PIP,
STR
blaTEM 50 50 AMP, PIP, STR blaTEM Conjugation
3.6. Class 1, 2, and 3 Integrons. Forty-seven E. coli isolates
were screened for the presence of integrases encoded on
class 1, 2, and 3 integrons. The class 1 integron-encoded
intI1 integrase gene was detected in 25 isolates while 4
isolates tested positive for class 2-encoded intI2 integrase.
One isolate, EC24, was found to harbor both intI1 and intI2.
No class 3 integron was detected. Majority of the integrons
were found to be plasmid-encoded (16 of the 25 intI1 and 3
of the 4 intI2 detected).
Isolates that were positive for class 1 and 2 integrons
were further analyzed for the presence of inserted gene
cassettes within the variable region by using the primer pair
5′ CS/3′ CS for class 1 integrons and primer pair orfx/attI2
for class 2 integrons. Amplified products of diﬀerent sizes
were obtained from 17 of the 25 intI1-positive isolates and
sequencing indicated the presence of 5 diﬀerent types of
known gene cassettes: aadA5-dfrA17, dfrA7, aadA1-aadB-
cmlA6, dfrA12-aadA2-orfF and aadA1. Using the attI2/orfX
primer pair for intI2-positive isolates resulted in a 2 kb
amplified product which, when sequenced, contained the
dfrA1-aadA1-sat2 gene cassette. The aadA2, aadA5, and
aadB genes encode resistance to aminoglycosides whereas
sat2 encode resistance to strepthoricin. Both dfrA12 and
dfrA17 encode resistance to trimethoprim and cmlA6 to
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chloramphenicol. Although trimethoprim and strepthoricin
were not used in our study, the presence of gene cassettes
encoding resistance to aminoglycosides and chlorampheni-
col coincided with the resistance profiles of the respective
isolates. The majority of the integron-positive isolates (24 of
27) were multidrug-resistant.
3.7. Transfer of Resistance Determinants. Conjugation exper-
iments were carried out for 7 randomly-selected ESBL-
producers and transfer of this phenotype to the recipient
nalidixic acid-resistant E. coli JM109 was successful in only 3
of the 7 isolates (38%). However, it should be noted that only
broth matings were carried out in this study and not filter
matings and thus the transmissibility potential for the other
4 isolates could not be fully ascertained. All transconjugants
were resistant to ampicillin and piperacillin except for the
EC18 which remained susceptible to piperacillin. Strepto-
mycin resistance was cotransferred in the EC46 transconju-
gant whereas for the EC31 transconjugant, trimethoprim-
sulfomethaxazole and cefoperazone resistances were also
transferred (Table 2).
Identical EcoRI and SphI restriction profiles were
obtained from plasmids extracted from the donor E. coli
and their respective transconjugants except for EC31. In this
case, based on the restriction profiles obtained, the plasmid
extracted from the transconjugant was smaller than the plas-
mid obtained from the donor EC31 strain (approximately
40 kb from the transconjugant as compared to ∼90 kb from
the donor) although they shared a number of common
restriction bands (Table 2). Plasmids extracted from the
transconjugants were used to transform electrocompetent
E. coli DH10B cells. Plasmids extracted from the resulting
ampicillin resistant DH10B transformants showed identical
EcoRI restriction profiles with those from their respective
transconjugants. The DH10B transformants also displayed
identical antibiotic resistance profiles as their respective
transconjugants, strongly implying that these antibiotic
resistance determinants were plasmid-borne.
Both blaTEM and intI1 were detected on the plasmids
extracted from the EC18 and EC46 donor, transconjugants as
well as their subsequent transformants indicating that these 2
genes were likely present on the plasmid that was transferred.
None of the common ESBL-encoding genes were detected
in EC31 although this isolate harbored class 1 integron-
encoded intI that was detected from the plasmid in the
EC31 transconjugant and transformant suggesting that the
transferred plasmid harbored a class 1 integron.
Transformation was carried out for the 4 isolates in
which conjugation was not successful and another ESBL-
positive randomly chose isolate. Plasmids were extracted
from these 5 isolates and electroporated into recipient E.
coli DH10B cells. All transformants obtained were resistant
to ampicillin, piperacillin, tetracycline, and trimethoprim-
sulfamethoxazole. Plasmids extracted from the transfor-
mants showed identical EcoRI restriction profiles when com-
pared to their respective donor plasmids except for isolate
EC7 in which the plasmid isolated from the transformant
was smaller (∼55 kb) when compared to the hospital isolate
(∼135 kb) (Table 2). Both blaTEM and intI1 genes were also
detected from the plasmids isolated from the donor isolates
as well as the transformants except for isolate EC7 and its
transformant.
4. Discussion
Genotyping by PCR-based methods and PFGE showed
the 47 E. coli clinical isolates to be genetically diverse
and heterogeneous. This is expected as the isolates were
randomly selected from diﬀerent hospitals and sources.
Similar observations were reported by Mugnaioli et al. [24]
andWoodford et al. [16]. We found that ERIC and REP-PCR
yielded practically identical results and able to diﬀerentiate
strains which were indistinguishable by RAPD. Although
PCR-based fingerprinting is rapid, it is more susceptible
to technical variations than PFGE especially reproducibility.
Thus PFGE is considered the better method for subtyping
of E. coli, even though it is relatively laborious and time-
consuming compared to PCR-based methods.
Isolates EC12 and EC24 were indistinguishable by both
PFGE and PCR fingerprints. These two blood isolates were
from diﬀerent patients in the same ward, strongly suggesting
a possible nosocomial spread. Interestingly, both isolates
harbored plasmids of diﬀerent sizes with EC12 harboring
a plasmid of ∼50 kb whereas EC24 contained a plasmid of
∼60 kb. On the other hand, there were isolates that were
identical in their PCR fingerprints but were diﬀerentiated
by their PFGE profiles (e.g., isolates EC14 and EC34) and
conversely, isolates that were indistinguishable by PFGE were
diﬀerentiated by PCR (isolates EC1 and EC4, and EC37 and
EC39). This shows that these methods are complementary
and a combined analysis would give a finer perspective
bearing inmind the drawbacks of each of these methods.
All 47 E. coli isolates analyzed in this study were
susceptible to imipenem. This finding is similar to previous
reports [16, 25]. Cefepime was equally sensitive at 98%which
is a rate higher than the 80% sensitivity reported in Colombia
[25] and 70% in China [26].
The resistance rates of chloramphenicol, trimethoprim-
sulfomethaxazole, tetracycline, gentamicin, kanamycin,
ciprofloxacin and nalidixic acid were 7% to 69% lower
compared to a report by Alhaj et al. [27].
The resistance rates of E. coli isolates to ceftazidime
(11%) and amoxillin-clavulanic acid (17%) were lower when
compared to that from China—28% for ceftazidime and
84% for amoxillin-clavulanic acid [26]. E. coli resistance to
amikacin in Malaysia (2% in this study) was still relatively
low compared to 27% in Colombia [25] or 22.4% in Israel
[28].
Forty E. coli isolates were classified as ESBL producers
based on phenotypic or genotypic detection of ESBL: 38
isolates were classified as ESBL producers based on the
genotypic detection of ESBL-encoding genes, and 2 others
were categorized as ESBL producers based on the double-
disk synergy and phenotypic confirmatory tests. However,
these two isolates, EC7 and EC31, did not harbor any of the
tested ESBL-encoding genes and may instead harbor other
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genes such as blaTLA, blaIMP, and blaCMY [1, 29] that were
not included in our test. Although the double-disk synergy
test had been reported to be reliable and easy-to-use, its
major disadvantage is that the distance of disk placement for
optimal sensitivity has not been standardized [20, 29].
Analysis of the ESBL-encoding genes indicated that the
majority of the ESBL-positive isolates harbored TEM-1
(88%) followed by CTX-M (20%), SHV (8%), and finally,
OXA (5%). TEM-1 has been reported to be responsible for
90% of ampicillin resistance in E. coli [30]. The blaCTX-M
gene is considered the most prevalent ESBL-encoding gene
worldwide and is replacing TEM and SHV types as the
predominant ESBL in many European countries [31]. The
presence of the blaSHV-5 gene in 11 ceftazidime resistant
E. coli isolates from one Malaysian teaching hospital has
been reported [6]. The specific SHV subtypes could not be
confirmed in this study as the primers used only amplified a
portion of the blaSHV reading frame.
Analysis of integron-encoded integrases indicated that
class 1 integron was the principal integron class in the
Malaysian strains. Class 2 integron was in theminority, and
no class 3 integron-encoded integrases were detected, a trend
that has previously been reported [14, 32]. Four diﬀerent
gene cassettes, namely, the aadA1, dfrA17-aadA5, dfrA12-
orfF-aadA2, and aadA1-aadB-cmlA6 were found in the class
1 integron-positive isolates, and these have been previously
described in E. coli as well as in other Enterobacteriaceae
[15]. All 4 isolates positive for class 2 integron-encoded
intI2 harbored the dfrA1-sat2-aadA1 gene cassette which
has been reported [1, 33]. Conjugation and transformation
experiments indicated that the majority of the integrons
and some of the ESBL-encoding genes (in particular blaTEM)
were plasmid-encoded and transmissible. Plasmids that were
isolated from the E. coli hospital isolates were estimated to
be larger than 50 kb in agreement with the sizes reported
previously [34, 35]. In 2 of the 3 successful conjugation
experiments, plasmids with identical restriction profiles were
isolated from the donor and the transconjugants. In the
remaining case, based on the restriction profiles obtained,
the plasmid that was isolated from the transconjugant was
about 50 kb smaller than the donor EC31 strain (∼90 kb),
indicating either that the donor strain harbored more than
a single type of plasmid and that only the plasmid of
about 40 kb was transferred, or that only a ∼40 kb portion
of the original plasmid was successfully transferred by
conjugation. The latter appeared to be a stronger possibility
as separation of undigested plasmid DNA extracted from
the parental EC31 strain seemed to indicate the presence of
a single plasmid. Similar observations were also noted for
the transformation experiments. Further characterization of
these plasmids is clearly needed and is the subject of our
on-going investigations. Nevertheless, our results indicate
that most of the ESBL-encoding genes especially blaTEM
are carried on plasmids which are transmissible suggesting
that the spread of ESBL and other antibiotic resistance
determinants is likely to be plasmid-mediated in agreement
with the conclusions made by other reports [36, 37] that
plasmids are one of the main vehicles for spread of antibiotic
resistance genes. This may have led to the high prevalence
of ESBL-producers and multidrug resistance among E. coli
hospital isolates in Malaysia.
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